Author:
Newton Michael,Wetzstein Gene,Sullivan Daniel
Reference163 articles.
1. Abigerges D, Armand JP, Chabot GG et al (1994) Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 86(6):446–449
2. Anton A, Aranda E (1998) Phase II study of irinotecan (cpt-11) in the treatment of patients with advanced colorectal cancer (acrc) resistant to 5-fluoracil (5-fu) based chemotherapy the experience of TTD Spanish cooperative group (meeting abstract). Proc Am Soc Clin Oncol 17:278a
3. Batchelor TT, Gilbert MR, Supko JG et al (2004) Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of nabtt 97–11. Neuro Oncol 6:21–27
4. Beppu K, Nakamura K, Linehan WM, Rapisarda A, Thiele C (2005) Topotecan blocks hypoxia-inducible factor-1α and vascular endothelial growth factor expression induced by insulin-like growth factor-1 in neuroblastoma cells. Cancer Res 65(11):4775–4781
5. Beran M, Estey E, O’Brien SM et al (1998) Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31:521–531
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献